High-Dose Platinum Combination Therapy in Pretreated Patients with Disseminated Melanoma
Background: There are no accepted second-line therapeutic options in patients with disseminated melanoma. We evaluated toxicity and efficacy of a combination therapy with cisplatin and carboplatin. Methods: Fifty consecutively treated melanoma patients who were progressive after at least one previou...
Gespeichert in:
| Veröffentlicht in: | Chemotherapy (Basel) 2007-01, Vol.53 (6), p.422-428 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 428 |
|---|---|
| container_issue | 6 |
| container_start_page | 422 |
| container_title | Chemotherapy (Basel) |
| container_volume | 53 |
| creator | Hofmann, Maja A. Gabriel, Verena Milling, Annett Kiecker, Felix Sterry, Wolfram Trefzer, Uwe |
| description | Background: There are no accepted second-line therapeutic options in patients with disseminated melanoma. We evaluated toxicity and efficacy of a combination therapy with cisplatin and carboplatin. Methods: Fifty consecutively treated melanoma patients who were progressive after at least one previous chemotherapy received cisplatin 100 mg/m 2 intravenously and carboplatin 200 mg/m 2 intravenously in a 2-day regimen once every 28 days. Results: As grade 3 and 4 toxicities, leucopenia (14%), thrombopenia (10%), anaemia (22%), nausea (8%), nephrotoxicity (4%), hypomagnesaemia (80%) and hepatotoxicity (2%) were observed. Among 42 patients evaluable for response, 2 (4.7%) had complete remission, 4 (9.5%) had partial remission and 21 (50%) had stable disease. The median progression-free time was 17 weeks (range 0–156) for all patients and 39 weeks (range 17–156) for patients with objective responses. The median overall survival time for all patients from the start of therapy was 32 weeks (range 2–156). Melanoma inhibitory activity levels of |
| doi_str_mv | 10.1159/000110007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_proquest_journals_223271824</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1383277971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c331t-ad5ba98a86e06249f7c0bd0e9765befcaeba3b032fde4ee39cd54cdab6bca2643</originalsourceid><addsrcrecordid>eNpFkM1Lw0AQxRdRbK0evIss3jxE9yMf3aOkaoWKPVTwFmaTSZvaJHV3g_S_d0uKvczwZn5vBh4h15w9cB6pR8YY574kJ2TIQ8EDlajwlAz9SAWSR8mAXFi79lLGkp-TAU9UJBgTQ_I1rZarYNJapPMNuKrpapq2ta4aL9qGLlZoYLujVUPnBp1BcFjQuV9i4yz9rdyKTiprsd47_OodN9C0NVySsxI2Fq8OfUQ-X54X6TSYfby-pU-zIJeSuwCKSIMawzhGFotQlUnOdMFQJXGkscwBNUjNpCgLDBGlyosozAvQsc5BxKEckbv-7ta0Px1al63bzjT-ZSaEFAkfiz1030O5aa01WGZbU9Vgdhln2T7C7D9Cz94eDna6xuJIHjLzwE0PfINZojkCvf8Pwrl1nA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223271824</pqid></control><display><type>article</type><title>High-Dose Platinum Combination Therapy in Pretreated Patients with Disseminated Melanoma</title><source>MEDLINE</source><source>Karger Journals</source><creator>Hofmann, Maja A. ; Gabriel, Verena ; Milling, Annett ; Kiecker, Felix ; Sterry, Wolfram ; Trefzer, Uwe</creator><creatorcontrib>Hofmann, Maja A. ; Gabriel, Verena ; Milling, Annett ; Kiecker, Felix ; Sterry, Wolfram ; Trefzer, Uwe</creatorcontrib><description>Background: There are no accepted second-line therapeutic options in patients with disseminated melanoma. We evaluated toxicity and efficacy of a combination therapy with cisplatin and carboplatin. Methods: Fifty consecutively treated melanoma patients who were progressive after at least one previous chemotherapy received cisplatin 100 mg/m 2 intravenously and carboplatin 200 mg/m 2 intravenously in a 2-day regimen once every 28 days. Results: As grade 3 and 4 toxicities, leucopenia (14%), thrombopenia (10%), anaemia (22%), nausea (8%), nephrotoxicity (4%), hypomagnesaemia (80%) and hepatotoxicity (2%) were observed. Among 42 patients evaluable for response, 2 (4.7%) had complete remission, 4 (9.5%) had partial remission and 21 (50%) had stable disease. The median progression-free time was 17 weeks (range 0–156) for all patients and 39 weeks (range 17–156) for patients with objective responses. The median overall survival time for all patients from the start of therapy was 32 weeks (range 2–156). Melanoma inhibitory activity levels of <12 ng/ml before therapy were identified to be associated with a favourable survival. Conclusion: Our results indicate that a combination of cisplatin and carboplatin in patients with pretreated disseminated melanoma has an acceptable safety profile, induces objective responses and may prolong survival.</description><identifier>ISSN: 0009-3157</identifier><identifier>EISSN: 1421-9794</identifier><identifier>DOI: 10.1159/000110007</identifier><identifier>PMID: 17952002</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carboplatin - administration & dosage ; Cisplatin - administration & dosage ; Clinical Study ; Dose-Response Relationship, Drug ; Drug therapy ; Female ; Humans ; Male ; Medical research ; Melanoma - drug therapy ; Melanoma - pathology ; Middle Aged ; Salvage Therapy ; Skin cancer ; Skin Neoplasms - drug therapy</subject><ispartof>Chemotherapy (Basel), 2007-01, Vol.53 (6), p.422-428</ispartof><rights>2007 S. Karger AG, Basel</rights><rights>(c) 2007 S. Karger AG, Basel.</rights><rights>Copyright (c) 2007 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c331t-ad5ba98a86e06249f7c0bd0e9765befcaeba3b032fde4ee39cd54cdab6bca2643</citedby><cites>FETCH-LOGICAL-c331t-ad5ba98a86e06249f7c0bd0e9765befcaeba3b032fde4ee39cd54cdab6bca2643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17952002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hofmann, Maja A.</creatorcontrib><creatorcontrib>Gabriel, Verena</creatorcontrib><creatorcontrib>Milling, Annett</creatorcontrib><creatorcontrib>Kiecker, Felix</creatorcontrib><creatorcontrib>Sterry, Wolfram</creatorcontrib><creatorcontrib>Trefzer, Uwe</creatorcontrib><title>High-Dose Platinum Combination Therapy in Pretreated Patients with Disseminated Melanoma</title><title>Chemotherapy (Basel)</title><addtitle>Chemotherapy</addtitle><description>Background: There are no accepted second-line therapeutic options in patients with disseminated melanoma. We evaluated toxicity and efficacy of a combination therapy with cisplatin and carboplatin. Methods: Fifty consecutively treated melanoma patients who were progressive after at least one previous chemotherapy received cisplatin 100 mg/m 2 intravenously and carboplatin 200 mg/m 2 intravenously in a 2-day regimen once every 28 days. Results: As grade 3 and 4 toxicities, leucopenia (14%), thrombopenia (10%), anaemia (22%), nausea (8%), nephrotoxicity (4%), hypomagnesaemia (80%) and hepatotoxicity (2%) were observed. Among 42 patients evaluable for response, 2 (4.7%) had complete remission, 4 (9.5%) had partial remission and 21 (50%) had stable disease. The median progression-free time was 17 weeks (range 0–156) for all patients and 39 weeks (range 17–156) for patients with objective responses. The median overall survival time for all patients from the start of therapy was 32 weeks (range 2–156). Melanoma inhibitory activity levels of <12 ng/ml before therapy were identified to be associated with a favourable survival. Conclusion: Our results indicate that a combination of cisplatin and carboplatin in patients with pretreated disseminated melanoma has an acceptable safety profile, induces objective responses and may prolong survival.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carboplatin - administration & dosage</subject><subject>Cisplatin - administration & dosage</subject><subject>Clinical Study</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical research</subject><subject>Melanoma - drug therapy</subject><subject>Melanoma - pathology</subject><subject>Middle Aged</subject><subject>Salvage Therapy</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - drug therapy</subject><issn>0009-3157</issn><issn>1421-9794</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpFkM1Lw0AQxRdRbK0evIss3jxE9yMf3aOkaoWKPVTwFmaTSZvaJHV3g_S_d0uKvczwZn5vBh4h15w9cB6pR8YY574kJ2TIQ8EDlajwlAz9SAWSR8mAXFi79lLGkp-TAU9UJBgTQ_I1rZarYNJapPMNuKrpapq2ta4aL9qGLlZoYLujVUPnBp1BcFjQuV9i4yz9rdyKTiprsd47_OodN9C0NVySsxI2Fq8OfUQ-X54X6TSYfby-pU-zIJeSuwCKSIMawzhGFotQlUnOdMFQJXGkscwBNUjNpCgLDBGlyosozAvQsc5BxKEckbv-7ta0Px1al63bzjT-ZSaEFAkfiz1030O5aa01WGZbU9Vgdhln2T7C7D9Cz94eDna6xuJIHjLzwE0PfINZojkCvf8Pwrl1nA</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Hofmann, Maja A.</creator><creator>Gabriel, Verena</creator><creator>Milling, Annett</creator><creator>Kiecker, Felix</creator><creator>Sterry, Wolfram</creator><creator>Trefzer, Uwe</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20070101</creationdate><title>High-Dose Platinum Combination Therapy in Pretreated Patients with Disseminated Melanoma</title><author>Hofmann, Maja A. ; Gabriel, Verena ; Milling, Annett ; Kiecker, Felix ; Sterry, Wolfram ; Trefzer, Uwe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c331t-ad5ba98a86e06249f7c0bd0e9765befcaeba3b032fde4ee39cd54cdab6bca2643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carboplatin - administration & dosage</topic><topic>Cisplatin - administration & dosage</topic><topic>Clinical Study</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical research</topic><topic>Melanoma - drug therapy</topic><topic>Melanoma - pathology</topic><topic>Middle Aged</topic><topic>Salvage Therapy</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hofmann, Maja A.</creatorcontrib><creatorcontrib>Gabriel, Verena</creatorcontrib><creatorcontrib>Milling, Annett</creatorcontrib><creatorcontrib>Kiecker, Felix</creatorcontrib><creatorcontrib>Sterry, Wolfram</creatorcontrib><creatorcontrib>Trefzer, Uwe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Chemotherapy (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hofmann, Maja A.</au><au>Gabriel, Verena</au><au>Milling, Annett</au><au>Kiecker, Felix</au><au>Sterry, Wolfram</au><au>Trefzer, Uwe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High-Dose Platinum Combination Therapy in Pretreated Patients with Disseminated Melanoma</atitle><jtitle>Chemotherapy (Basel)</jtitle><addtitle>Chemotherapy</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>53</volume><issue>6</issue><spage>422</spage><epage>428</epage><pages>422-428</pages><issn>0009-3157</issn><eissn>1421-9794</eissn><abstract>Background: There are no accepted second-line therapeutic options in patients with disseminated melanoma. We evaluated toxicity and efficacy of a combination therapy with cisplatin and carboplatin. Methods: Fifty consecutively treated melanoma patients who were progressive after at least one previous chemotherapy received cisplatin 100 mg/m 2 intravenously and carboplatin 200 mg/m 2 intravenously in a 2-day regimen once every 28 days. Results: As grade 3 and 4 toxicities, leucopenia (14%), thrombopenia (10%), anaemia (22%), nausea (8%), nephrotoxicity (4%), hypomagnesaemia (80%) and hepatotoxicity (2%) were observed. Among 42 patients evaluable for response, 2 (4.7%) had complete remission, 4 (9.5%) had partial remission and 21 (50%) had stable disease. The median progression-free time was 17 weeks (range 0–156) for all patients and 39 weeks (range 17–156) for patients with objective responses. The median overall survival time for all patients from the start of therapy was 32 weeks (range 2–156). Melanoma inhibitory activity levels of <12 ng/ml before therapy were identified to be associated with a favourable survival. Conclusion: Our results indicate that a combination of cisplatin and carboplatin in patients with pretreated disseminated melanoma has an acceptable safety profile, induces objective responses and may prolong survival.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>17952002</pmid><doi>10.1159/000110007</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-3157 |
| ispartof | Chemotherapy (Basel), 2007-01, Vol.53 (6), p.422-428 |
| issn | 0009-3157 1421-9794 |
| language | eng |
| recordid | cdi_proquest_journals_223271824 |
| source | MEDLINE; Karger Journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Cisplatin - administration & dosage Clinical Study Dose-Response Relationship, Drug Drug therapy Female Humans Male Medical research Melanoma - drug therapy Melanoma - pathology Middle Aged Salvage Therapy Skin cancer Skin Neoplasms - drug therapy |
| title | High-Dose Platinum Combination Therapy in Pretreated Patients with Disseminated Melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T15%3A38%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High-Dose%20Platinum%20Combination%20Therapy%20in%20Pretreated%20Patients%20with%20Disseminated%20Melanoma&rft.jtitle=Chemotherapy%20(Basel)&rft.au=Hofmann,%20Maja%20A.&rft.date=2007-01-01&rft.volume=53&rft.issue=6&rft.spage=422&rft.epage=428&rft.pages=422-428&rft.issn=0009-3157&rft.eissn=1421-9794&rft_id=info:doi/10.1159/000110007&rft_dat=%3Cproquest_karge%3E1383277971%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223271824&rft_id=info:pmid/17952002&rfr_iscdi=true |